Harrow ( NASDAQ: HROW ) stock rises 16% premarket after it announced the successful manufacture of the first of three commercial-scale process performance qualification batches of TRIESENCE 40 mg/mL. TRIESENCE is a preservative-free synthetic corticosteroid that is FDA‐approved for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids. Harrow also announced that the second and third required PPQ batches are now scheduled; and should these PPQ batches meet specifications, the new TRIESENCE production process will be deemed complete, allowing Harrow to relaunch during 2024.
Source: Press Release More on Harrow Health Harrow, Inc. 2024 Q1 - Results - Earnings Call Presentation Harrow, Inc. (HROW) Q1 2024 Earnings Call Transcript Harrow: Merits A Buy On Sales Potential Harrow Health Non-GAAP EPS of -$0.
28 misses by $0.07, revenue of $34.59M misses by $2.
68M Seeking Alpha’s Quant Rating on Harrow Health.
